文献速递MDS 与骨髓增殖性肿瘤血栓与止血

真性红细胞增多症与原发性血小板增多症:2019年诊断、风险分层与管理更新

Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
PubMed 文献 · Am J Hematol · 2018-11-09

该综述更新了真性红细胞增多症(PV)和原发性血小板增多症(ET)的诊断、风险分层与治疗。骨髓形态学是诊断基石,JAK2突变见于PV,约90%的ET患者表达JAK2、CALR或MPL突变。治疗目标是预防血栓出血并发症,PV需放血使血细胞比容低于45%并每日阿司匹林81 mg,高危ET和PV推荐降细胞治疗,首选羟基脲。

要点

  • PV中位生存14年,ET为20年;年轻患者分别为24年和33年。
  • ET的10年白血病转化率估计<1%,PV为3%。
  • PV高危为年龄>60岁或血栓史;ET分极低、低、中、高危四层。

核心结论

  • PV和ET的主要治疗目标是预防血栓出血并发症。
  • 所有PV患者需放血使血细胞比容低于45%,并每日一次或两次阿司匹林81 mg(无禁忌时)。
  • 极低危ET可能无需治疗,低危ET建议(弱推荐)阿司匹林治疗。
  • 高危ET和PV推荐降细胞治疗,中危ET不强制。
  • ET和PV降细胞治疗一线首选羟基脲,二线首选干扰素-α和白消安。

研究设计与样本

  • 综述,检索范围未报告。

主要发现

  • PV中位生存14年,ET为20年;年轻患者分别为24年和33年。
  • 某些突变(主要为剪接体)和异常核型可能损害PV和ET的生存。
  • ET的预期寿命低于对照人群。
  • 驱动突变未显示影响ET生存。
  • JAK2突变ET血栓风险更高。

关键数值与推荐

  • PV风险分层:高危(年龄>60岁或血栓史)和低危(两者均无)。
  • ET风险分层:极低危(年龄≤60岁、无血栓史、JAK2野生型)、低危(同极低危但JAK2突变阳性)、中危(年龄>60岁、无血栓史、JAK2野生型)、高危(血栓史或年龄>60岁且JAK2突变)。
  • PV诊断中JAK2突变预期存在;约90%的ET患者表达互斥的JAK2、CALR或骨髓增殖性白血病突变。
  • ET诊断中排除纤维化前骨髓纤维化最重要。

临床怎么用

  • PV:放血使血细胞比容<45%,每日一次或两次阿司匹林81 mg(无禁忌时)。
  • 极低危ET可能无需治疗;低危ET建议(弱推荐)阿司匹林。
  • 高危ET和PV推荐降细胞治疗;中危ET不强制。
  • 降细胞治疗一线首选羟基脲,二线首选干扰素-α和白消安。
  • 不推荐PV使用ruxolitinib,除非严重持续瘙痒或明显脾大且对上述药物无反应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Disease Overview: Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms respectively characterized by erythrocytosis and thrombocytosis; other disease features include leukocytosis, splenomegaly, thrombosis, bleeding, microcirculatory symptoms, pruritus, and risk of leukemic or fibrotic transformation. Diagnosis: Bone marrow morphology remains the cornerstone of diagnosis. In addition, the presence of JAK2 mutation is expected in PV while approximately 90% of patients with ET express mutually exclusive JAK2, CALR, or myeloproliferative leukemia mutations. In ET, it is most important to exclude the possibility of prefibrotic myelofibrosis. Survival: Median survivals are 14 years for PV and 20 years for ET; the corresponding values for younger patients are 24 and 33 years. Certain mutations (mostly spliceosome) and abnormal karyotype might compromise survival in PV and ET. Life-expectancy in ET is inferior to the control population. Driver mutations have not been shown to affect survival in ET. Risk of thrombosis is higher in JAK2-mutated ET. Leukemic transformation rates at 10 years are estimated at <1% for ET and 3% for PV. Thrombosis Risk: In PV, 2 risk categories are considered: high (age > 60 years or thrombosis history present) and low (absence of both risk factors); in ET, 4 risk categories are considered: very low (age ≤ 60 years, no thrombosis history, JAK2 wild-type), low (same as very low but JAK2 mutation present), intermediate (age > 60 years, no thrombosis history, JAK2 wild-type) and high (thrombosis history present or age > 60 years with JAK2 mutation). Risk-Adapted Therapy: The main goal of therapy in both PV and ET is to prevent thrombohemorrhagic complications. All patients with PV require phlebotomy to keep hematocrit below 45% and once- or twice-daily aspirin (81 mg), in the absence of contraindications. Very low-risk ET might not require therapy while aspirin therapy is advised for low-risk disease. Cytoreductive therapy is recommended for high-risk ET and PV but it is not mandatory for intermediate-risk ET. First-line drug of choice for cytoreductive therapy, in both ET and PV, is hydroxyurea and second-line drugs of choice are interferon-α and busulfan. We do not recommend treatment with ruxolutinib in PV, unless in the presence of severe and protracted pruritus or marked splenomegaly that is not responding to the aforementioned drugs.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. Am J Hematol. 2018. PMID: 30281843. doi:10.1002/ajh.25303

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。